Greenpark Compounding Pharmacy (Prescription Labs, Inc.), Houston, TX
Is Greenpark Compounding Pharmacy (Prescription Labs, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Greenpark Compounding Pharmacy (Prescription Labs, Inc.) hold a Texas pharmacy license?
No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file does list GREENPARK COMPOUNDING PHARMACY & GIFTS, HOUSTON, a close but not exact match shown below.
Has Greenpark Compounding Pharmacy (Prescription Labs, Inc.) had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Aug 12, 2021) for Greenpark Compounding Pharmacy (Prescription Labs, Inc.). Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Prescription Labs, Inc.; Greenpark Compounding Pharmacy
- Location
- Houston, TX
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Sep 17, 2021
- FDA Data Dashboard inspections
- 2 inspections: 2 OAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 10 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Prescription Labs, Inc. (dba Greenpark Compounding Pharmacy), a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Sep 17, 2021 | Press release or statement | FDA Press Release : FDA alerts patients and health care professionals not to use compounded products intended to be sterile from Prescription Labs Inc. dba Greenpark Compounding Pharmacy (09/17/2021) | FDA copy (archived) |
| Aug 12, 2021 | Form 483 | 483 Issued 08/12/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Prescription Labs Inc, Houston, TX (FEI number 3009712882), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 12, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3009712882 | 1148654 |
| Oct 27, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3009712882 | 1031376 |
Form 483s FDA has published for this site
- Aug 12, 2021: Form 483 to Prescription Labs Inc, published Sep 17, 2021. fda.gov
- Apr 12, 2018: Form 483 to Prescription Labs Inc, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 10 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 2, 2021 to Aug 12, 2021: 10 observations
- Firm on the cover
- Prescription Labs Inc dba Greenpark, 406LF Bellaire Blvd, Producer of Sterile and Non-sterile Drugs
- FEI number
- 3009712882
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Personnel engaged in aseptic processing were observed with exposed skin.
Specifically, on 7/2/2021, I observed your pharmacy technician while aseptically processing the sterile drug product, Vancomycin-PF Ophthalmic 1.5% 10 ML Soln, Lot# <Redacted B4>, BUD 7/30/2021, Qty <Redacted B4> units break the plain of the ISO 5 LAFU. exposing M facial skin while wearing a non-sterile hairnet, non-sterile eyeglasses, and non-sterile face mask inside the ISO-5 LAFU, which may directly affect drug quality. This is a repeat observation.
Observation 2
Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
Specifically, during a review of selected 3rd Party Contract Laboratory Sample Results, 1 found your pharmacy failed to reject out of specification products before and after dispensing them to patients and dispensed the drug product after the beyond use date. Additionally, your pharmacy continued to dispense after laboratory 00S results were received. For example:
a.
<Redacted B6> Dispensed Date: I0/22/2020
(6) ( 6 J, b.
<Redacted B4> Dispensed Date: 9/30/2020
c.
<Redacted B4> Dispensed Date: 9/8/2020
d.
<Redacted B4> Dispensed Date: 9/16/2020
e.
<Redacted B4> Dispensed Date: 9/4/2020
f.
<Redacted B4> Dispensed Date: I0/1/2020
g.
<Redacted B4> Dispensed Date: 10/7/2020
h. <Redacted B4> Dispensed Date: 11/23/2020
Sample ID- Sample <Redacted B4>, Tacrolirnus PF 5ml Aqueous Ophthalmic suspension 0.02%, Lot# <(Redacted B4> , specification <Redacted B4>, Actual Results <Redacted B4> (Actual <Redacted B4> ) (Laboratory Test Date: 7/16/2020), BUD 10/24/2020. Pharmacy dispensing patient-specific-prescriptions include:
a. ...
Observation 3
used to sterilize products.
Specifically, your pharmacy failed to perform a <Redacte d B4> test on all sterile <R edacted B4> use d to ren der the drug product, Spironolactone- PF Ophth. Each 15ML, 0.005 MG.ML, Soln of 770ML, L ot # <Redacted B4>, BUD 1/26/2022 sterile. For example, your p harmacy uses <Redacted B4>. Your formula worksheet fail to list the <Redacted B4> and upon completion of aseptic processing perform a <Redacted B4> test to ensure <Redacted B4> integrity. Spironolactone-PF-Ophth other sterilization steps after the <Redacted B4>. Your pharmacy has processed <Redacted B4> different batches <Redacted B4> units) over the past 12 months which the <Redacted B4> was not tested. This is a repeat Observation.
Observation 4
No assurance that sterile drug products were processed and stored under ISO 5 quality air.
Specifically,
A. On 8/2/2021 while visually observing your pharmacy technician aseptically process the drug product, Spironolactone-PF-Ophth Each 15ML, 0.005 MG/ML Soln of 770ML, Lot # <Redacted B4> BUD I /26/2022, dropper container kit packages and bottles were observed blocking tbe return vent in the ISO S LAFU while the technician was aseptically <Redacted B4> -the Spironolactone-PF Ophthalmic and then transferring to the eye dropper bottles.
C. Tacrolimus-PF Aqueous Ophthalmic SML 0.2% Suspension processing includes <Redacted B4> preventing the movement of first pass air. Tacrolimus Pf Aqueous Ophthalmic does not undergo other sterilization steps after the <Redacted B4> there is no further sterilization step to the process. -
Observation 5
IS0-5 classified areas were not certified under dynamic conditions.
Specifically, uni-directional airflow was not verified under operational conditions. For example, on July 15, 2021, your pharmacy failed to recertify the airflow, air quality, and performed no environmental monitoring prior to resuming aseptic production, resulting from the replacement of the <Redacted B4> AC unit designated for the entire cleanroom and ISO 5 LAFU built into the room (non-standalone unit); where aseptic processing occurs. The designated AC unit provides both the make-up air and cooling for all areas of the cJeanroom. Your firm management reported only cleaning occurred with no justification for not performing a recertification prior to resuming aseptic production activities.
Observation 6
The facility design was observed to allow the influx. of poor quality air into a higher classified area.
SpecificaJly,
A. No HEPA filter coverage is available for the <Redacted B4> located in cleanroom for Suite "' <Redacted B4> Room) and Suite <Redacted B4> Room) <Redacted B4> cleanrooms containing LAFU and BSC, which may potentially allow the influx of poor quality air into a higher classified area. Furthermore, there are spaces between and edges of the doors.
cleanrooms containing LAFU and BSC, which may potentially allow the influx of poor quality air into a higher classified area. Furthermore, there are spaces between and edges of the doors. B. <Redacted B4> doors are designed with no continuous monitoring and no alarms in place to notify of changes in differential pressure in the event both doors are opened simultaneously along with spaces between and edges.
Observation 7
Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
Specifically, your pharmacy failed to establish procedures for the deactivation of hazardous drug components used in the production of sterile and non-sterile drug products. For example:
A. Your pharmacy produced the sterile drug product, <Redact ed B4>, Testosterone Cypionat e in Sesame Oil Injection, 10ML 200mg/ML Solution within Cleanroom Suite < Redacted B4>. Your pharmacy also uses the same aseptic process suite for other non-hazardous drug products. Your pharmacy president and technician reported no special cleaning practices other than using ste ri le <Reda cted B4> and <Redacted B 4> .
The steril e <Reda cted B4> used <Redacted B4>. No deac tivation agents are used.
B. Your pharmacy produced the non-sterile drug product, Biestrogen (50/50) l .8MG/ML 0.18%
Cream, < Redacted B4> , BUDl/12/2022 in the same non-sterile production area as the d rug prod uct, <Re dacted B4>. Clobet asol in <Redact ed B4> each 60GM 0.05% CREAM, L ot # <Redacted B4> BUD l 0/2/2021. ...
Observation 8
You did not appear to use biological indicators <Redacted B4> during <Redacted B4> and <Redacted B4> of finished drug products. Consequently, it is unclear if the sterilization conditions are adequate for inactivating all potential microbial contamination.
Specifically, your pharmacy utilizes <Redacted B4> without the use of bio indicators. For example, no bio indicators were used while <Redacted B4> the drug product, <Redacted B6> , Testosterone Cypionate in Sesame Oil Injection 10ML 200mg/ml SOLN, Lot# <Redacted B4> BUD 11/1/2021; Atropine Sulfate Ophthalmic 10ML .2% Solution, Lot # <Redacted B4> BUD 9/27f2021 ; and <Redacted B4> Hydroxyprogesterone in Sesame Oil Injection 5ML MDV* 250MG/ML SOLN, Lot# <Redacted B4> , BUD 11/23/2021.
Observation 9
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
Specifically, your pharmacy employees' media fill reports dated 2/1/2021 and procedure, "Personnel Aseptic Media Fill Testing and Process, P-402.2", Section 6.2, Sample Procedure for High Risk Level Compounding; failed to adequately represent your pharmacy's most complex aseptic manipulation activity. For example, your pharmacy's media fill procedure failed to include representative manipulation activities, documented within the sterile drug product, Acetylcysteine Ophthalmic each l0ML I 0%Soln, Lot # <Redacted B4> BUD 9/21/2021, which was dispensed to patient-specific prescription, <Redacted B6>. Media fill simulation selection are to represent the most difficult aseptic manipulations and most interventions, which has the potential of introducing microbials and/or alter the final drug quality through stressing the aseptic technique and ISO 5 processing area. ...
Observation 10
ISO-5 classified areas were not certified under dynamic conditions.
Specifically uni-directional airflow was not verified under operational (dynamic) conditions for your pharmacy's documented recertification report for the ISO S LAFU and ISO 5 BSC dated 8/9/2021.
Linked 483s whose text is not shown
- Apr 12, 2018: FDA document 108730: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.
Close but not exact board records
These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.
- License 34761, GREENPARK COMPOUNDING PHARMACY & GIFTS, HOUSTON, status Active: same city, one name is a longer form of the other.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Texas State Board of Pharmacy license file
- Texas State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.